Skip to main content
Premium Trial:

Request an Annual Quote

GlaxoSmithKline Licenses New Version of Rosetta Resolver Software Development Kit

Premium

GlaxoSmithKline has become the first company to license the Rosetta Resolver Software Development Kit version 2.0.

The kit will allow GlaxoSmith- Kline, which already has licensed Rosetta’s flagship Rosetta Resolver microarray data analysis software, to customize Resolver for its own research.

According to Rosetta Biosoftware, Software Development Kit (SDK) users can incorporate their own error models and clustering algorithms via the system’s open application program interfaces [APIs]. Error models are plugged in using Java technology, while clustering algorithms are incorporated using both C++ and Java.

“The Rosetta Resolver SDK will allow us to access the Rosetta Resolver system’s open APIs,” stated Paul Matthews, project leader of gene expression bioinformatics at GlaxoSmithKline.” Our internal bioinformatics staff will make use of the open APIs to extend the system and integrate it with our internally developed algorithms and bioinformatics solutions.”

This agreement signals not only Rosetta Resolver’s continuing popularity among pharmaceutical companies, but also pharma’s confidence that Rosetta’s Biosoftware division is separate enough from Merck, which owns Rosetta Inpharmatics, to ensure that data will be secure.

Glaxo’s data will be “accessible to the Biosoftware division, but not accessible to Merck,” said Myra Ozaeta, a spokeswoman for Rosetta’s Biosoftware division. “Legal documents protect this [arrangement].”

Rosetta officially launched the Biosoftware division on September 20, and appointed Doug Bassett as vice president and general manager. The division recently moved to its new headquarters in Kirkland, Wash., a short distance from Rosetta Inpharmatics’ offices.

The Biosoftware division aims to operate quasi-independently of Merck, and is free to license the software and form contracts with Merck’s competitors. “They understand that in order to keep our products successful, we need to do business with customers the way we used to,” Ozaeta said.

The company did not disclose financial details of the agreement.

— MMJ

 

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.